|drug1071||Drug: NA-831 - 0.10 mg/kg Wiki||1.00|
|drug2524||Placebo- 1.00 mg/kg Wiki||1.00|
|drug2522||Placebo- 0.10 mg/kg Wiki||1.00|
|drug1072||Drug: NA-831 - 0.20 mg/kg Wiki||1.00|
|drug2523||Placebo- 0.20 mg/kg Wiki||1.00|
|drug2525||Placebo- 2.00 mg/kg Wiki||1.00|
|drug2466||Placebo 0.20 mg + 2.00 mg/kg Wiki||1.00|
|drug1075||Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) Wiki||1.00|
|drug2465||Placebo 0.10 mg + 1.00 mg/kg Wiki||1.00|
|drug1065||Drug: GS-5734 - 1.00 mg/kg Wiki||1.00|
|drug1076||Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg) Wiki||1.00|
|drug1066||Drug: GS-5734 - 2.00 mg/kg Wiki||1.00|
|D009410||Nerve Degeneration NIH||0.71|
|D012141||Respiratory Tract Infections NIH||0.17|
|D014777||Virus Diseases NIH||0.11|
There is one clinical trial.
Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices. This test will be developed using innovative technology developed at the Parc Taulí University Hospital, which increases the immunogenicity of SARS-CoV-2 differential antigens. The increased immunogenicity of these antigens will allow to detect, with a high sensitivity and specificity, the antibodies in the serum of patients infected with SARS-CoV-2. This test will serve to confirm dubious results as well as reduce false negatives from the PCR test, which will ultimately help reduce transmission of the infection.
Description: IgG antibodies against COVID-19 RBDMeasure: IgG anti-COVID-19 Time: From May to July
Description: IgM antibodies against COVID-19 RBDMeasure: IgM anti-COVID-19 Time: From May to July
Description: IgA antibodies against COVID-19 RBDMeasure: IgA anti-COVID-19 Time: From May to July
Description: Qualitative result to clasify patients into PCR COVID-19 positive patients and PCR COVID-19 negative patientsMeasure: COVID-19 PCR results Time: From May to July
Description: The presence or abcense of the typical image of the pneumonia caused by COVID-19Measure: Radiological studies Time: From May to July
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports